Citations

Clear

69 citation(s) found for "Sehgal, S".

Performance of Google NotebookLM for AI-assisted data extraction and consensus statement generation in a heterogenous systematic review on inflammatory bowel disease, obesity, and cardiometabolic comorbidities: A Methodological Report
Samaan, Sami , Devi, Jalpa , VINCENT, Matthew, Coombs, Shannon , Sehgal, Priya , Mohamed, Mouhand , Rai, Victoria , Johnson, Amanda M. , Yarur, Andrés , Barnes, Edward L. , Mohamed, Mouhand F H , Yarur, Andres J , Deepak, Parakkal , Barnes, Edward L , Devi, Jalpa , Sehgal, Priya , Coombs, Shannon , Deepak, Parakkal

Mayo Clinic

No container title available | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.16.26355773 | PMID 42396330 Get It

Abstract Background Large language models (LLMs) offer promise for systematic review data extraction, but performance in complex multidisciplinary domains and utility for clinical statement generation remain insufficiently described. Objectives To evaluate Google NotebookLM for AI-assisted data extraction and RAND/UCLA consensus statement generation in a systematic review of IBD, obesity, and cardiometabolic comorbidities. Methods Studies were organized into domain-specific notebooks; structured prompts generated standardized evidence tables. Two independent reviewers validated outputs against full-text articles using a four-category error classification. Cell-level accuracy and critical accuracy (cells free of major factual errors) were the primary metrics; workflow time was compared against a published conventional extraction benchmark. Concordance between AI-generated and expert-finalized statements was assessed. Results Across 57 articles, 1,710 data cells were extracted; 151 (8.83%) were flagged, yielding 91.17% cell-level accuracy. Major factual errors occurred in only 4 cells (0.23%), for a critical accuracy of 99.77%. Most errors were minor omissions (59.6%) or incomplete extractions (30.5%); domain error rates ranged from 7.08% to 11.33%. The pipeline required 17.7 versus a projected 165.1 person-hours (89.3% reduction). PICO-structured prompting generated 70 candidate statements; 58 of 112 finalized panel statements (51.8%) were AI-derived, and 85.7% were retained in the finalized set. Conclusion Google NotebookLM demonstrates feasibility as a primary extraction and synthesis tool in a multidisciplinary systematic review, with extractive incompleteness as the principal limitation and substantial time savings over conventional approaches. Its novel application to RAND/UCLA consensus statement generation extends AI-assisted evidence synthesis to clinical consensus generation workflow.
Modulate Obesity and relateD metabolic complIcations For Yielding improvements in IBD outcomes (MODIFY-IBD): consensus on obesity and cardiometabolic comorbidities in inflammatory bowel disease using systematic reviews and the RAND/UCLA appropriateness met
Devi, Jalpa , Samaan, Sami , Vincent, Matthew, Coombs, Shannon , Doering, Michelle , Barnes, Edward L, Johnson, A, Yarur, Andres J, Mohamed, Mouhand , Devi, Jalpa , Sehgal, Priya , VINCENT, Matthew, Barnes, Edward L., Yarur, Andrés , Deepak, Parakkal

Mayo Clinic

BMJ Open | May 26, 2026 | Volume: 16 | Issue: 5 | Pages: e115709

10.1136/bmjopen-2025-115709 | PMID 42191195 Get It

Introduction Obesity and related cardiometabolic comorbidities, including hypertension, dyslipidaemia, diabetes, metabolic dysfunction-associated steatotic liver disease and atherosclerotic cardiovascular disease, are increasingly prevalent among individuals with inflammatory bowel disease (IBD). These conditions influence disease activity, therapeutic response, surgical outcomes and overall quality of life, yet evidence remains fragmented. The M odulate O besity and relate D metabolic compl I cations F or Y ielding improvements in IBD outcomes (MODIFY-IBD) initiative aims to synthesise evidence and generate consensus recommendations to guide practice and future research in this area. This study describes a protocol for a structured evidence synthesis and Research ANd Development/University of California, Los Angeles (RAND/UCLA) Appropriateness Method (RUAM) consensus process. Methods and analysis We will conduct three systematic reviews and a structured evidence synthesis organised into three domains: (1) the impact of obesity on IBD outcomes, (2) the burden of cardiometabolic complications in IBD and (3) the management of overweight, obesity and cardiometabolic comorbidities in IBD. A multidisciplinary international panel of gastroenterologists, surgeons, endocrinologists, hepatologists, cardiologists and dietitians will assess each statement using the RAND/UCLA appropriateness method. Panellists will rate the appropriateness of each statement (only those that fall within their area of expertise) on a 1–9 scale (1–3=inappropriate, 4–6=uncertain and 7–9=appropriate), with medians rounded up (eg, 6.5=appropriate). Agreement will be assessed using the RAND Disagreement Index (DI<1.0=agreement). Ethics and dissemination This study will not involve direct patient participation, as it is based on evidence synthesis and expert consensus; therefore, formal research ethics committee approval will not be required. Patient representatives will contribute to the consensus process to provide contextual perspectives but no identifiable data will be collected. Findings will be disseminated through publication in peer-reviewed journals, presentation at major gastroenterology and IBD conferences and communication with professional societies. A lay summary and patient-friendly infographic will also be developed to facilitate translation of recommendations into clinical practice. PROSPERO registration numbers CRD420251178843: a systematic review of the impact of obesity on inflammatory bowel disease outcomes. CRD420251178799: a systematic review of cardiometabolic complications in inflammatory bowel disease. CRD420251174653: management of overweight, obesity and cardiometabolic comorbidities in inflammatory bowel disease: a systematic review.
Ketamine Use in Self-Described Therapeutic Contexts: A Thematic Analysis of Reddit Posts
Kendrick, J. Richard, Ahmad, Ghonwa, Wood, Audrey, Stumo, Samuel , Sehgal, Aarav, Matthews, Douglas B. , Sharma, Pravesh , Sharma, Pravesh , Matthews, Douglas B , Kendrick, Jared

Mayo Clinic

Behavioral Sciences | March 25, 2026 | Volume: 16 | Issue: 4 | Pages: 480

10.3390/bs16040480 | PMID 42073843 Get It

The use of ketamine for the management of neuropsychiatric conditions outside clinical settings has rapidly expanded, creating a critical need to understand diverse individual experiences. We conducted a qualitative content analysis of posts from the r/TherapeuticKetamine subreddit. From 3302 threads, the 500 highest-engagement threads (12,852 comments) were analyzed by independent coders across six domains: perceived positive effects, adverse effects, reasons for use, route of administration, polydrug use, and dose amounts. Mood-related concerns were the primary reason for use (53%). Users reported positive effects, most often improvements in emotional well-being (65%). Adverse effects were predominantly psychological or mood-related (56%). A total of 70% of reported doses exceeded 149 mg, suggesting a trend toward higher dose use. Intravenous administration (40%) and sublingual troches (23%) were the most frequently reported routes. Concurrent use of prescribed psychotropics, cannabis, and psychedelics was also reported. This analysis identified substantial heterogeneity in individual-reported experiences. Frequent high-dose use, dose escalation, and polydrug exposure underscores the importance of clinical monitoring and attention to addiction potential and drug–drug interactions. The findings should be interpreted with caution, as follow-up and clinical verification were not possible; however, the data provide an unfiltered view of individual experiences in relation to ketamine use outside the clinical setting.
Abstract DP154: The Association Between Comprehensive Evaluation in ESUS and Stroke Recurrence: A secondary analysis of the Cardiac Abnormalities in Stroke Prevention and risk of Recurrence Study
Stretz, Christoph, Lewis, Skylar, Chahien, Dalia, Eklund, Kelsey , Khasiyev, Farid, Kasab, Sami Al, D'Souza, Marissa, Kerrigan, Deborah , Sharma, Richa, Nour, Hassan Osama Mostafa Aboul, Nahab, Fadi, Omran, Setareh Salehi , Linares, Guillermo , Sehgal, Siddharth, Singh, Eesha , Zha, Alicia , Mannion, Shani, Chen, Lucia , Thompson, Sean, Thon, Jesse, Penckofer, Mary , Yu, Wenzheng, Qdais, Ahmad Abu, Dumitrascu, Oana, Talat, Fawad , Kang, Jieun, Aziz, Yasmin, Zubair, Adeel , Havenon, Adam de, Bowman, Anna , Shahrivari, Mahan, Liebeskind, D, Nedelcu, Simona , Ali, Hamid , Kam, Wayneho , Nguyen, Thanh N., Herpich, Franziska , Farooqui, Mudassir, Rojas-Soto, Diana , Yaghi, Shadi, Khan, Fahad , Stretz, Christoph , Siegler, James E. , Lineback, Christina , Kasab, Sami Al , Culbertson, Collin J , D’Souza, Marissa , Stamm, Brian , Ro, Jennifer , Sharma, Richa , Nour, Hassan Aboul , Peter, Shani , Thon, Jesse , Jillella, Dinesh , Sloane, Kelly L , Aziz, Yasmin , Brorson, James R. , Farooqui, Mudassir

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp154 Get It

Background: Although the embolic stroke of undetermined source (ESUS) construct was proposed as a unifying concept for embolic-appearing strokes without an identified cause, it includes patients with diverse and often unrecognized underlying mechanisms. This study investigates the differential rate of recurrent stroke according to the completeness of neurodiagnostic testing in a diverse multicenter cohort. Methods: This was a retrospective analysis of a multicenter observational cohort study (n=27 sites). Patients with ESUS were categorized into three groups: (1) established mechanism after further work up (ESUS-E), (2) patients who underwent a comprehensive diagnostic workup without an identified etiology (ESUS 2.0), and (3) no advanced workup (ESUS-NAW). The primary outcome of recurrent ischemic stroke was assessed by comparing ESUS 2.0 to both ESUS-E and ESUS-NAW groups using adjusted Cox proportional hazards models. Results: Of the 2,281 patients included, 694 (30%) were classified as ESUS-E, 344 (15%) as ESUS 2.0, and 1,443 (55%) as ESUS-NAW. The ESUS 2.0 group had a significantly lower annualized recurrence rate (1.98 per 100 person-years) compared to both the ESUS-NAW group (7.7 per 100 person-years; aHR 0.27, 95% CI: 0.11–0.62; p=0.002) and the ESUS-E group (6.10 per 100 person-years; aHR = 0.35; 95% CI 0.15–0.85, p=0.020). Within the ESUS-E group, cancer (aHR 5.33; 95% CI: 2.09–13.63; p < 0.001) and non-stenosing atherosclerotic disease or arch atheroma (aHR 3.40; 95% CI: 1.18–9.83; p = 0.023) were associated with significantly increased risk of recurrence when compared to ESUS 2.0. Conclusion: These findings demonstrate a lower risk of recurrent stroke in patients classified as ESUS 2.0, diverging from the 5–6% annual recurrence rates observed in prior ESUS trials. These findings suggest that patients who receive comprehensive diagnostic evaluation without identification of a specific etiology have a lower risk of recurrent stroke, an important consideration for the design of future ESUS studies.
Real-World Outcomes of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Obese Patients With Ulcerative Colitis and IPAA With a History of Pouchitis
Desai, Aakash , Habib, Hany , Khataniar, Himsikhar , Sehgal, Priya , Kochhar, Gursimran , Sehgal, Priya , Kochhar, Gursimran S , Desai, Aakash , Farraye, Francis A. , Barnes, Edward L. , Hashash, Jana G.

Mayo Clinic

Inflammatory Bowel Diseases | November 19, 2025 | Volume: 32 | Issue: 5 | Pages: 869-874

10.1093/ibd/izaf301 | PMID 41365321 Get It

Abstract Introduction There are limited data on the impact of glucagon-like peptide-1 receptor agonist (GLP-1RA) on the risk of recurrent pouchitis after ileal pouch–anal anastomosis (IPAA) for ulcerative colitis (UC). Methods A retrospective cohort study was conducted in the TriNetX Research Network in adult patients with obesity and IPAA for UC with a history of pouchitis in whom a GLP-1RA was initiated compared to those patients in whom a GLP-1RA was not initiated. The primary outcome was the risk of recurrent pouchitis within 12 months. The secondary outcomes were mean number of antibiotic prescriptions, anti-diarrheal medication use, Crohns-like disease of pouch (CLDP), and pouch excision. One-to-one propensity score matching was performed. Results We identified 43 UC-IPAA patients with obesity and history of pouchitis (mean age 51.7 ± 14.7 years, mean body mass index [BMI] 34.4 ± 6 kg/m2, 60.4% female). After propensity score matching, the GLP-1RA cohort had a significantly decreased risk of recurrent pouchitis (26.3% vs 52.6%; adjusted odds ratio [aOR], 0.32; 95% CI, 0.12-0.84) compared to the control cohort. Mean antibiotic prescriptions were numerically lower in the GLP-1RA cohort (2 vs 4.4, P = .16). Anti-diarrheal medication use was lower in the GLP-1RA cohort (18.4% vs 47.3%; aOR, 0.23; 95% CI, 0.07-0.67). There was no difference in the risk of CLDP. Zero patients required pouch excision in both cohorts. Conclusion Our study in a small cohort of patients with UC-IPAA and obesity with a history of pouchitis showed that GLP-1RA use was associated with decreased risk of recurrent pouchitis and anti-diarrheal medication use.
Intracranial Occlusion in Cryptogenic Stroke Is Not Predictive of Recurrent Ischemic Stroke: A Propensity‐Score Matched Analysis of the Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence Study
Brorson, James R. , Badillo‐Goicoechea, Elena , Penckofer, Mary , Eklund, Kelsey , Stretz, Christoph , Lineback, Christina M. , Khasiyev, Farid , Kerrigan, Deborah , Lewis, Skylar, Ali, Hamid , Melkumova, Emiliya , Dumitrascu, Oana M. , Parikh, Parth , Doolittle, Charles, Yahnke, Ian, Sathya, Anvitha , Brown, Samantha , Kang, Jieun, Bowman, Anna, Shahrivari, Mahan, Sehgal, S , Alvi, Muhammad , Krishnaiah, Balaji , Kam, Wayneho , Kothari, Sachin , Qdais, Ahmad Abu, Quintela, Gustavo Antezana, Sharma, Richa, Thottempudi, Neeharika, Nedelcu, Simona , Herpich, Franziska , Glover, Patrick , Chahien, Dalia, Liebeskind, David S. , Linares, Guillermo , Daniel, Jean‐Philippe, Kasab, Sami Al , Singh, Eesha , D’Souza, Maria , Gaudio, Elizabeth, Kala, Narendra , Sarkar, Monica , Coevering, Russell J. Van , Thon, Jesse , Thompson, Sean, Lineback, Christina , Brorson, James R , Penckofer, Mary , Eklund, Kelsey , Stretz, Christoph , Lineback, Christina M , Khasiyev, Farid , Kerrigan, Deborah , Ali, Hamid , Aboul-Nour, Hassan , de Havenon, Adam H , Culbertson, Collin J , Melkumova, Emiliya , Jillella, Dinesh V , Dumitrascu, Oana M , Parikh, Parth , Sathya, Anvitha , Brown, Samantha J , Elangovan, Cheran , Sehgal, Siddharth , Sloane, Kelly L , Krishnaiah, Balaji , Kam, Wayneho , Kothari, Sachin , Farooqui, Mudassir , Nahab, Fadi B , Sharma, Richa , Nedelcu, Simona , Herpich, Franziska , Liebeskind, David S. , Linares, Guillermo , Al Kasab, Sami , Aziz, Yasmin , Yaghi, Shadi , Goldstein, Eric D , Van Coevering, Russell J , Thon, Jesse , Stamm, Brian , Siegler, James E , Lineback, Christina M , Daniel, Jean-Philippe Auguste , Smith, Matthew M. , Nour, Hassan Aboul , Havenon, Adam de , Jillella, Dinesh , Doolittle, Charles, Elangovan, Cheran , Sharma, Richa , Thottempudi, Neeharika , D'Souza, Marissa, Aziz, Yasmin , Yaghi, Shadi , Goldstein, Eric , Chen, Lucia , Stamm, Brian , Siegler, James E.

Mayo Clinic

Journal of the American Heart Association | September 25, 2025 | Volume: 14 | Issue: 19 | Pages: No page available

10.1161/jaha.125.041500 | PMID 40996035 Get It

Background Intracranial occlusions in embolic stroke of undetermined source are histopathologically similar to cardiac sources of embolism. Whether patients with embolic stroke of undetermined source and intracranial occlusion benefit from anticoagulation is unknown. Methods A multicenter retrospective cohort of adults with cryptogenic stroke was queried for patients with proximal or medium/distal vessel occlusion. The primary outcome was recurrent ischemic stroke, which was assessed in unadjusted and adjusted Cox proportional hazards models and repeated following 1:1 propensity score matching and biweight kernel density matching. Results Of the 2328 patients who were followed over a median of 1.31 years (interquartile range, 0.34–2.85), 999 (42.6%) had an intracranial occlusion. When compared with patients without an intracranial occlusion, those with an occlusion had fewer atherosclerotic vascular risk factors, more severe symptoms, and less severe cerebral microvascular disease. The rate of recurrent stroke was similar between patients with versus without an intracranial occlusion (6.8%/year [95% CI, 5.7–8.2] versus 7.0%/year [95% CI 6.0–8.1]; adjusted hazard ratio [HR], 1.09 [95% CI, 0.77–1.55]). There was no association between occlusion and recurrent stroke in the adjusted propensity score matching (HR, 1.01 [95% CI, 0.64–1.59]) or kernel density models (HR, 0.95 [95% CI, 0.62–1.45]). There was no interaction between occlusion and treatment with anticoagulation, sex, age, or high‐risk sources of embolism for the primary outcome in the unmatched and matched analyses. Conclusions Intracranial occlusion in patients with embolic stroke of undetermined source is not associated with a greater risk of recurrence when compared with patients without an intracranial occlusion. There was no difference in rate of recurrent stroke with anticoagulation when stratified by presence or absence of occlusion.
Outcomes of Patients With Embolic Stroke of Undetermined Source Treated With Antiplatelet Agents or Anticoagulation
Siegler, James E. , Badillo‐Goicoechea, Elena , Penckofer, Mary , Eklund, Kelsey , Yaghi, Shadi , Stretz, Christoph , Lineback, Christina , Stamm, Brian , Peter, Shani , D’Souza, Marissa , Conyers, Frank, Khasiyev, Farid , Kerrigan, Deborah , Lewis, Skylar, Ali, Hamid , Nour, Hassan Aboul , Sharma, Richa, Glover, Patrick , Thompson, Sean, Alshaer, Qasem , Thottempudi, Neeharika, Melkumova, Emiliya , Chionatos, Rafail , Daniel, Jean-Philippe Auguste, Frankel, Michael , Dumitrașcu, Oana , Parikh, Parth , Doolittle, Charles, Yahnke, Ian, Sathya, Anvitha , Kang, Jieun , Kirchhoffer, Kaitlyn, Bowman, Anna, Smith, M. J., Asabere, Aaron, Shahrivari, Mahan, Sheibani, Nazanin , Krishnaiah, Balaji , Gaudio, Elizabeth, Rothstein, Aaron , Alvi, Muhammad M. , Annam, Saketh , Amankwah, Curtis , Kam, Wayneho , Abburi, Nandini , Rojas-Soto, Diana , Molaie, Amir , Khezri, Nicole, Zubair, Adeel , Abbasi, Mehdi , Coevering, Russell J. Van , Nedelcu, Simona , Herpich, Franziska , Chahien, Dalia, Sehgal, Siddharth, Liebeskind, David S. , Linares, Guillermo , Zha, Alicia , Sarkar, Monica , Xi, Romi, Nelson, Ashley, Qdais, Ahmad Abu, Kasab, Sami Al , Singh, Eesha , Patel, Vivek , Mehndiratta, Prachi , DeMarco, Alexis, Cucchiara, Brett , Omran, Setareh Salehi , Dubinski, Michael , Ackerman, Jiyoun, Thon, Jesse , Brown, Samantha , Siegler, James E , Goicoechea, Elena Badillo , Lineback, Christina M , Conyers, F Garrett , Aboul-Nour, Hassan , Sharma, Richa , Nahab, Fadi B , Glover, Patrick , Alshaer, Qasem N , de Havenon, Adam H , Melkumova, Emiliya , Chionatos, Rafail A , Jillella, Dinesh V , Frankel, Michael R , Dumitrascu, Oana M , Sathya, Anvitha , Smith, Matthew M , Brorson, James R , Elangovan, Cheran , Krishnaiah, Balaji , Sloane, Kelly L , Rothstein, Aaron , Alvi, Muhammad M , Kam, Wayneho , Abburi, Nandini , Farooqui, Mudassir , Molaie, Amir , Zubair, Adeel , Abbasi, Mehdi , Van Coevering, Russell J , Nedelcu, Simona , Liebeskind, David S. , Linares, Guillermo , Zha, Alicia , Abu Qdais, Ahmad , Al Kasab, Sami , Aziz, Yasmin , Mehndiratta, Prachi , Sharrief, Anjail , Cucchiara, Brett L , Salehi Omran, Setareh , Nguyen, Thanh N , Thon, Jesse , Yaghi, Shadi , Stretz, Christoph , Penckofer, Mary , Khasiyev, Farid , Brown, Samantha J , Eklund, Kelsey , Stamm, Brian , Daniel, Jean-Philippe Auguste , D'Souza, Marissa , Sharma, Richa , Thottempudi, Neeharika , Havenon, Adam de , Culbertson, Collin J , Jillella, Dinesh , Daniel, Jean-Philippe Auguste, Ro, Jennifer , Brown, Samantha, Doolittle, Charles, Brorson, James R. , Asabere, Aaron, Elangovan, Cheran , Chen, Lucia , Aziz, Yasmin , Nguyen, Thanh N. , Ackerman, Jiyoun

Mayo Clinic

Neurology | July 3, 2025 | Volume: 105 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000213876 | PMID 40609061 Get It

Real-world use of bezlotoxumab to prevent recurrent Clostridioides difficile infections: a single-center experience and meta-analysis
Sehgal, Kanika , Berry, Parul , Pardi, Darrell S. , Khanna, Sahil , Tariq, Raseen , Khanna, S , Tariq, Raseen

Mayo Clinic

Therapeutic Advances in Gastroenterology | June 21, 2025 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/17562848251346593 | PMID 40547251 Get It

Background: Clostridioides difficile infection (CDI) treated with bezlotoxumab (BEZ) has been demonstrated to have a lower recurrence rate than placebo in clinical trials. However, real-world data on BEZ’s effectiveness remain limited and heterogeneous. Objectives: To evaluate the real-world effectiveness of BEZ in preventing CDI recurrence through a single-center retrospective cohort and a meta-analysis. Design: A retrospective cohort study and a meta-analysis. Methods: A retrospective study of patients treated with BEZ from 2017 to 2021 was performed at the Mayo Clinic. Demographics, CDI diagnostics, and several prespecified risk factors were analyzed. A literature search was conducted in August 2024 utilizing the Cochrane Central Register of Controlled Trials, Embase, Medline, Scopus, and Web of Science Core Collection. Studies reporting CDI resolution rates with BEZ were included. The random-effects model described by DerSimonian and Laird was used to calculate weighted pooled resolution rates (WPR) with 95% confidence intervals (CI). We assessed heterogeneity with the inconsistency index ( I 2 ) statistic. Results: Across 28 studies and our retrospective cohort, 2639 CDI patients were analyzed. Among 1786 patients treated with BEZ, 1450 achieved clinical resolution (WPR: 81.6%, 95% CI 77.2–85.6%), with significant heterogeneity ( I ² = 77.3%). In subgroup analysis, the pooled relative risk of recurrence was 0.56 (95% CI 0.36–0.88; p < 0.01) for BEZ with SoC compared to SoC alone. A WPR of 83.3% (95% CI 75.5%–91.1%) for patients receiving BEZ with SoC was observed when compared with a WPR of 70.8% (95% CI 62.7%–78.8%) in patients receiving SoC alone on subgroup analysis. In our cohort of 47 patients, the CDI resolution rate was 72.3% (34/47). Conclusion: Our retrospective study and meta-analysis demonstrate the real-world efficacy of BEZ in reducing CDI recurrence. The higher recurrence rates in our cohort likely reflect the high-risk nature of the population, including a greater proportion of immunocompromised patients.
Impact of Marine Microplastics on Neurologic and Functional Disabilities: A Population‐Level Study
Makwana, Bhargav , Desai, Brinda, Srinivasan, Jayashri, Apetauerova, Diana, Sehgal, Siddharth, Yerstein, Oleg , Nasir, Khurram , Kong, Yixin , Rajagopalan, Sanjay , Al‐Kindi, Sadeer , Ganatra, Sarju , Ganatra, Sarju , Desai, Brinda, Dani, Sourbha S. , Khadke, Sumanth , Kumar, Ashish , Wadhera, Rishi K. , Navas‐Acién, Ana , Adamkiewicz, Gary , Moffatt‐Bruce, Susan D.

Mayo Clinic

European Journal of Neurology | May 21, 2025 | Volume: 32 | Issue: 5 | Pages: No page available

10.1111/ene.70144 | PMID 40396917 Get It

ABSTRACTBackgroundMicroplastics are emerging as environmental pollutants with potential neurotoxic effects, yet their association with neurological disabilities remains largely unexplored.MethodsIn this cross‐sectional study comprising 218 coastal counties in the United States, we compared the self‐reported prevalence of cognitive disability, mobility disability, self‐care disability, and independent living disability in counties with very high and low marine microplastic levels (MMLs). Unadjusted and adjusted prevalence ratios (PRs) were computed using population‐weighted quasi‐Poisson regression across three different models to examine the relationship between disability prevalence and MMLs.ResultsCounties exposed to very high marine microplastic levels had a higher mean prevalence of self‐reported cognitive disability (15.2% vs. 13.9%), mobility disability (14.1% vs. 12.3%), self‐care disability (4.2% vs. 3.6%), and independent living disability (8.5% vs. 7.7%) compared to those exposed to low levels (p < 0.001). Regression analyses revealed significantly elevated adjusted prevalence ratios (PRs) for cognitive (PR: 1.09 [95% CI: 1.06–1.12], p < 0.001), mobility (PR: 1.06 [1.03–1.10], p < 0.001), self‐care (PR: 1.16 [1.11–1.20], p < 0.001), and independent living disability (PR: 1.08 [1.05–1.12], p < 0.001) in counties with very high microplastic exposure compared to those with low exposure.ConclusionsThis study highlights a significant association between marine microplastic pollution and the self‐reported prevalence of cognitive, mobility, self‐care, and independent living disabilities at the county level. While merely associative, these findings emphasize the urgent need for further investigation into the individual‐level health impacts of microplastic exposure and underscore the importance of environmental interventions to mitigate potential risks.
Body mass index changes after fecal microbiota transplantation for recurrent Clostridioides difficile infection
Sehgal, Kanika , Berry, Parul , Cho, Janice , Saffouri, George, Dierkhising, Ross , Battaglioli, Eric , Kashyap, Purna , Pardi, Darrell S. , Khanna, Sahil , Pardi, Darrell

Mayo Clinic

Therapeutic Advances in Gastroenterology | February 24, 2025 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/17562848251321121 | PMID 39996135 Get It

Background: Fecal microbiota transplantation (FMT) is a successful therapy for Clostridioides difficile infection (CDI). FMT from overweight donors is speculated to influence the recipient’s body mass index (BMI) after administration for CDI. Objectives: We investigated changes in the recipient’s BMI after FMT in relation to the donor’s BMI. Design: We conducted a retrospective cohort study involving patients who underwent FMT for recurrent CDI at Mayo Clinic between 2012 and 2019. Methods: We analyzed demographic and donor data for patients undergoing FMT at Mayo Clinic (2012–2019). Recipient BMI (pre- and post-FMT) and donor BMI were extracted from medical records. Mixed-effects linear regression was used to evaluate the impact of donor BMI, donor BMI category, recipient baseline BMI, time before and after FMT, and interactions between these variables on overall BMI change and BMI change per month. Kaplan–Meier curves were used to assess BMI changes (⩾5 units) based on the last recorded post-FMT BMI. Results: We analyzed data from 401 patients with recorded BMI measurements before and after FMT. The median age of the recipients at the time of FMT was 59.1 years (interquartile range (IQR): 40.5–70.1 years), with 61.6% being female. The median BMI for recipients prior to FMT was 26.7 kg/m² (IQR: 22.7–31.6 kg/m²), while the median BMI of the donors was 24.5 kg/m2 (IQR: 23.9–27.5 kg/m2). Stool from donors with a normal BMI was used for 58.2% of recipients, while 41.8% received stool from pre-obese donors. Donor BMI data were missing for 3.2% of recipients. Donor BMI was not significantly associated with changes in recipient BMI; for each 1-unit increase in donor BMI, a 0.01-unit monthly increase was observed (95% confidence interval: −0.0003, 0.02; p = 0.11). The log-rank test for BMI increases (⩾+5) and decreases (⩽−5) revealed no significant differences among the donor BMI groups (Chi-squared = 4.4, p = 0.1 for increases, Chi-squared = 2, p = 0.4 for decreases). Conclusion: The lack of impact of donor BMI on BMI changes post-FMT suggests that these changes are more dependent on the recipient’s metabolic profile. Prospective, controlled trials are required to analyze these results more comprehensively.